1	
2	
3	Machine learning for the prediction of spontaneous preterm birth using early
4	second and third trimester maternal blood gene expression: A Cautionary Tale
5	
6	Kylie K Hornaday*1¶, Ty Werbicki1¶, Suzanne C Tough ^{2,3} , Stephen L Wood ⁴ , David W
7	Anderson ^{5#} , Donna M Slater ^{1,4}
8	
9 10 11	¹ Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
12 13 14	² Department of Community of Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
15 16 17	³ Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
18 19 20	⁴ Department of Obstetrics and Gynaecology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
20 21 22 23	⁵ Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Alberta, Canada
24 25 26	[#] Current address: Department of Science, Langara College, Vancouver, British Columbia, Canada
27	
28	*Corresponding author
29	E-mail: kylie.hornaday@ucalgary.ca (KKH)
30	[¶] These authors contributed equally to this work

It is made available under a CC-BY 4.0 International license .

31 Abstract

Preterm birth (PTB) remains a significant global health challenge and a leading cause of 32 neonatal mortality and morbidity. Despite advancements in neonatal care, the prediction of PTB 33 remains elusive, in part due to complex etiologies and heterogeneous patient populations. This 34 35 study aimed to validate and extend information on gene expression biomarkers previously 36 described for predicting spontaneous PTB (sPTB) using maternal whole blood from the All Our 37 Families pregnancy cohort study based in Calgary, Canada. The results of this study are two-38 fold: first, using additional replicates of maternal blood samples from the All Our Families cohort, we were unable to repeat the findings of a 2016 study which identified top maternal gene 39 40 expression predictors for sPTB. Second, we conducted a secondary analysis of the original gene 41 expression dataset from the 2016 study, including external validation using a pregnancy cohort 42 based in Detroit, USA. While initial results of our machine learning model suggested promising performance (area under the receiver operating curve, AUC 0.90 in the training set), performance 43 was significantly degraded on the test set (AUC 0.54), and further degraded in external 44 validation (AUC 0.51), suggesting poor generalizability, likely due to overfitting exacerbated by 45 46 a low feature-to-noise ratio. Prediction was not improved when using machine learning approaches over traditional statistical learning. These findings underscore the challenges in 47 48 translating biomarker discovery into clinically useful predictive models for sPTB. This study 49 highlights the critical need for rigorous methodological safeguards and external validation in biomarker research. It also emphasizes the impact of data noise and overfitting on model 50 51 performance, particularly in high-dimensional omics datasets. Future research should prioritize

It is made available under a CC-BY 4.0 International license .

robust validation strategies and explore mechanistic insights to improve our understanding andprediction of PTB.

54

55

56 Introduction

Preterm birth, defined as delivery of a live infant prior to 37 weeks of gestation, occurs in 57 58 13.4 million births worldwide, and is a significant contributor to mortality and morbidity in 59 neonates and children under five [1, 2]. While approximately one third of preterm births occur following known maternal or fetal indications, the remaining two thirds occur following 60 61 spontaneous onset of labour and/or premature rupture of the fetal membranes (sPTB) without 62 known indication, making prediction and subsequent clinical management of those at risk 63 challenging [2]. Child mortality related to PTB complications has declined since 2000, in part due to advancements in treatments for neonatal complications of prematurity such as respiratory 64 distress syndrome (RDS). However, an estimated 900,000 PTB-associated deaths of children 65 under five still occurred in 2019 worldwide [3]. 66 67 As one of the great obstetrical syndromes, the ability to predict sPTB may be key to

As one of the great obstetrical syndromes, the ability to predict SPTB hay be key to
improving outcomes. Indeed, considerable efforts have aimed to identify predictive biomarkers
of sPTB, however none so far have emerged to have clinical utility, possibly due to
heterogeneity within both patient populations and preterm birth phenotypes, as well as risk of
bias within study design [4-7]. Methodological safeguarding and appropriate validation of
models is important to determine the feasibility, repeatability, robustness, and generalizability of
prediction [8-11]. Best practices for prediction modelling are well defined in the literature [12,

13], and primary research articles reporting external validation of prediction models have been increasingly published over the last five years [14-17]. However, studies externally validating prediction models in the reproductive field are limited [10, 18, 19]. Additionally, strategies to qualify and understand heterogeneity and regular updating and assessment of predictive models is important to ensure best practice and clinical utility for prediction [20]. Thus, we sought herein to determine the predictive relationship between gene expression biomarkers and spontaneous preterm birth, and to repeat and validate previous findings on prediction of sPTB.

Gene expression biomarkers have been identified in maternal whole blood for the 81 82 prediction of sPTB, which presents a promising avenue for minimally invasive prediction as 83 peripheral blood can reflect global and uterine physiological and immunological changes during pregnancy [21]. One example includes eight genes, LOC100128908, MIR3691, LOC101927441, 84 85 CST13P, ACAP2, ZNF324, SH3PXD2B, TBX21 that were identified as significantly predictive of sPTB (65% sensitivity and 88% specificity after adjusting for history of abortion and anaemia) in 86 87 a stepwise logistic regression model [22]. These gene expression biomarkers were identified 88 using an Affymetrix chip microarray analysis of maternal whole blood from the All Our Families pregnancy cohort based in Calgary, Canada [22]. The All Our Families pregnancy cohort 89 presents a rare opportunity for testing experimental repeatability, as maternal blood samples 90 91 were collected and stored in four separate PAXgene RNA tubes, two were used for the original 92 study (22), and one for validating RNA quality and integrity [23], leaving a remaining fourth 93 sample for experimental validation. The study herein sought to use the additional PAXgene tube to repeat and validate this predictive model to test feasibility for clinical use. 94 95 Further, though the original study, which used a logistic regression based model,

96 presented promising predictive performance, we hypothesized that machine learning approaches

It is made available under a CC-BY 4.0 International license .

97 could improve predictive performance. Machine learning and other complex data analysis 98 methods are particularly well suited for mining high dimensional datasets, such as transcriptomic 99 datasets, as they do not generally require the data to adhere to any *a priori* assumptions [24]. 100 Machine learning allows for the identification of non-obvious, interactive, complex, and/or non-101 linear patterns which can go undetected when using traditional statistical linear models [24, 25]. 102 These patterns can be leveraged both toward outcome prediction (something highly valuable for 103 complex medical conditions such as preterm birth) and characterizing underlying disease 104 mechanisms [26, 27]. This is particularly enticing, as the underlying causes of sPTB remain 105 poorly understood. The authors have identified an external pregnancy cohort based in Detroit, 106 USA for external validation of both regression- and machine learning-based prediction of sPTB 107 to determine the generalizability of prediction. Prediction algorithms that match too closely to 108 the training data, in other words, suffer from overfitting, are not generalizable to other 109 populations, which is one of the major limitations of machine learning and other methods for 110 prediction. This problem is exacerbated by small or non-representative training sets, where 111 patterns identified may not be meaningfully associated with the outcome, or "noise" and thus the prediction does not translate effectively beyond the original training observations. This stresses 112 113 the importance of external validation in order to identify robust, generalizable models to 114 meaningfully push forward the prediction of preterm birth.

The overarching aim is to explore the repeatability, generalization, and robustness of a
prediction model for sPTB using maternal blood gene expression biomarkers. Specific aims are
as follows:

It is made available under a CC-BY 4.0 International license .

118	1.	To test the predictive utility of LOC100128908, MIR3691, LOC101927441, CST13P,
119		ACAP2, ZNF324, SH3PXD2B, TBX21 expression in maternal blood as biomarkers of
120		spontaneous preterm birth.
121	2.	To externally validate a prediction model for spontaneous preterm birth using maternal
122		blood gene expression data with machine and statistical learning.
123		
124		

```
125 Methods
```

126 Biological samples and validation of top biomarkers

To test the reproducibility of top biomarkers identified in the literature, historical 127 128 biological samples were collected from the All Our Families cohort [28-30]. In brief, participants 129 were recruited between May 1st, 2008 and December 31st, 2011 at <25 weeks gestation and 130 provided consent for blood sample collection, and complete questionnaires including information 131 related to demographics, emotional and physical health. Participants provided informed written 132 consent at the time of recruitment from healthcare offices, community and through Calgary Laboratory services and were provided copies of their consent forms for their records. This study 133 134 was approved by the Conjoint Health Research Ethics Board at the University of Calgary 135 #REB15-0248 Predicting Preterm Birth Study. Biological samples were collected at two points 136 in pregnancy, timepoint 1 (T1) at 17-23 weeks gestation and timepoint 2 (T2) 28-32 weeks 137 gestation. Maternal whole blood was collected directly into four separate PAXgene blood RNA 138 tubes which were then stored at -80°C prior to RNA isolation (PAXgene Blood RNA Kit, 139 Qiagen). Samples were de-identified prior to data collection. Two tubes were previously used for 140 the original prediction modelling and biomarker identification by Heng et al., [22], a third tube

141	was used to assess RNA integrity in long term storage [23], and a fourth was collected from
142	storage from August 16th to November 3rd, 2018 for use in the current study. For the current
143	study, n=47 participants who subsequently had an sPTB (<37 weeks) were included (n=44 T1,
144	n=42 T2 samples), in addition to n=45 participants who had a healthy term (38-42 weeks)
145	delivery (n=40 T1, n=44 T2). A total of n=13 samples were missing from storage or insufficient
146	sample remaining (n=3 T1 sPTB, n=3 T2 sPTB, n=5 T1 term, n=2 T2 term), and n=2 T2 samples
147	in the sPTB group were not included as delivery occurred prior to the second sample collection.
148	Maternal blood samples were collected, and RNA was isolated according to manufacturer's
149	instructions (RNAeasy minikit, Qiagen). The following genes were measured using a probe-
150	based assay (Quantigene, Invitrogen, ThermoFisher Scientific), which uses identical probes to an
151	Affymetrix microarray chip: LOC100128908 (LMLN2), LOC101927441, CST13P, ACAP2,
152	ZNF324, SH3PXD2B, TBX21. Due to limitations with measuring microRNA (miRNA) using the
153	assay, MIR3691 was not measured.
154	
155	
156	Novel prediction model
157	Population and expression dataset
158	To test whether machine learning could improve predictive performance, a secondary
159	analysis of the maternal blood microarray data, as previously published [22], was conducted.
160	Gene expression data was downloaded as raw Affymetrix Chip output files from the National

- 161 Center for Biotechnology Information Gene Expression Omnibus (accession number:
- 162 GSE59491) (All Our Families, AOF- Calgary cohort) [22]. The dataset used herein contains
- high-throughput expression data from n=165 subjects (n=51 sPTB, n=114 matched term delivery

164	controls) nested within the Calgary AOF cohort. Matched gene expression data from two
165	timepoints, 17-23 weeks (T1) and 28-33 weeks (T2) was available for each participant. Two
166	observations from the sPTB group were removed from the dataset as these deliveries occurred
167	prior to the T2 collection and therefore have only one expression dataset. An external dataset was
168	additionally identified from a pregnancy cohort based in Detroit, USA [31], which collected
169	maternal blood samples at comparable timepoints for gene expression analysis, (accession
170	number: GSE149440), and was used for external validation of the model. Participants that had at
171	least two matched blood samples collected within the same two timeframes (T1 and T2) were
172	selected from within the Detroit cohort dataset for analysis, for a total of n=98 subjects (n=34
173	sPTB and n=64 matched term delivery controls) included for external validation.
174	
175	Differential expression analysis
176	The Calgary dataset was randomly split into 80:20 training and test sets, and the differential
177	expression analysis was conducted on the training set with 2 times 5-fold cross validation
178	Differential expression analysis was performed initially as described previously [22]. In brief,
178 179	Differential expression analysis was performed initially as described previously [22]. In brief, differential expression was explored using the following comparisons:
178 179 180	 Differential expression analysis was performed initially as described previously [22]. In brief, differential expression was explored using the following comparisons: sPTB group compared to term group at T1
178 179 180 181	 Differential expression analysis was performed initially as described previously [22]. In brief, differential expression was explored using the following comparisons: sPTB group compared to term group at T1 sPTB group compared to term group at T2
178 179 180 181 182	 Differential expression analysis was performed initially as described previously [22]. In brief, differential expression was explored using the following comparisons: sPTB group compared to term group at T1 sPTB group compared to term group at T2 T1 compared to T2 in sPTB group
178 179 180 181 182 183	 Differential expression analysis was performed initially as described previously [22]. In brief, differential expression was explored using the following comparisons: sPTB group compared to term group at T1 sPTB group compared to term group at T2 T1 compared to T2 in sPTB group T1 compared to T2 in term group
178 179 180 181 182 183 184	 Differential expression analysis was performed initially as described previously [22]. In brief, differential expression was explored using the following comparisons: sPTB group compared to term group at T1 sPTB group compared to term group at T2 T1 compared to T2 in sPTB group T1 compared to T2 in term group dT (T2-T1) in sPTB compared to term
178 179 180 181 182 183 184 185	 Differential expression analysis was performed initially as described previously [22]. In brief, differential expression was explored using the following comparisons: sPTB group compared to term group at T1 sPTB group compared to term group at T2 T1 compared to T2 in sPTB group T1 compared to T2 in term group dT (T2-T1) in sPTB compared to term Genes with a family-wise error rate less than 0.05 were considered differentially expressed and

It is made available under a CC-BY 4.0 International license .

187

188 Feature selection analysis

Three features from each differentially expressed gene were fed into the downstream 189 190 modelling pipeline: the log2 of its intensity value at T1 (T1), the log2 of its intensity value at T2 191 (T2), and the difference between these two measurements (T2-T1, or dT). Input data for feature 192 selection included all genetic features and their associated target labels (sPTB or term group) for 193 the training set. Feature selection was conducted using a supervised stepwise feature selection 194 approach using two times five-fold cross validation. In brief, this stepwise additive approach to 195 feature selection iteratively includes each feature and retains only those features that significantly 196 improve the training model. The feature selection algorithm assigns a gene score for each feature 197 as a measure of relative importance, and subsequently discards non-explanatory or noisy 198 features.

199

200 Model training and testing

Each training set was fitted using two learning algorithms: logistic regression (LR) and multilayer perceptron artificial neural network (MLP). Hyperparameters for MLP model training were selected using the *Hyperopt* package, and models were evaluated using two repeats of fivefold stratified cross validation. The resultant two models were assessed for predictive performance by fitting them on the internal (Calgary) test set, or the external (Detroit) dataset. Full details on the computational methods are described elsewhere [32].

208 **Results**

It is made available under a CC-BY 4.0 International license .

209 Validation of biomarkers of preterm birth

Demographic characteristics of the population used for biomarker validation are 210 211 described in Table 1. Participants with an sPTB did not significantly differ from the term group 212 in age, smoking status, alcohol use during pregnancy, history of abortion, history of PTB, gravidity or parity. Of the biomarkers measured, only five of seven were detectable in the study 213 214 population (Table 2, S2 Table). Samples were tested at four concentrations (1.875, 3.75, 6.25, 215 25ng/uL RNA standards). Biomarkers CST13P and LMLN2 were below the limit of detection (<LOD) in over 50% of the population (68% and 56% respectively) at all concentrations and 216 thus were excluded from further analysis. One sample (term T2) was <LOD across all 217 218 biomarkers, which was likely a technical issue with sample processing and thus excluded. Levels 219 of SH3PXD2B were <LOD in 22% of the population and those <LOD were assigned as one half 220 of the basement level (3 MFI, mean fluorescence index units). The remaining four biomarkers 221 were present above the limit of detection in all samples.

222 Table 1. Patient demographic and clinical characteristics

	sPTB	Term
	(n=47)	(n=45)
Maternal age (years)	31.5[30.2-32.8]	31.8[30.6-33.0]
Maternal ethnicity		
White	37, 79[64-89]%	35, 78[63-89]%
Non-white	10, 21[11-36]%	10, 22[11-37]%
Smoking during pregnancy		
Yes	5, 11[4-23]%	10, 22[11-37]%
No	36, 77[62-88]%	34, 76[60-87]%
Unknown	6, 13[5-26]%	1, 2[0.06-12]%
Alcohol during pregnancy		
Yes	17, 36[23-52]%	24, 53[38-68]%
No	22, 47[32-62]%	18, 40[26-56]%
Unknown	8, 17[8-31]%	3, 7[1-18]%
History of abortion		

It is made available under a CC-BY 4.0 International license .

Yes	4, 9[2-20]%	8, 18[8-32]%
No	43, 91[80-98]%	37, 82[68-92]%
History of PTB		
Yes	8, 17[8-31]%	2, 4[0.5-15]%
No	39, 83[69-92]%	43, 96[85-99]%
Gravidity	1.9[1.6-2.2]	1.9[1.7-2.2]
Parity	0.6[0.3-0.8]	0.5[0.4-0.7]
Gestational age at delivery	22 0[22 2 24 6]	20 2[28 0 20 4]
(weeks)	55.9[55.2-54.0]	39.2[38.9-39.4]

Values are represented as mean[95% confidence interval] for continuous variables or n, %[95% 223 confidence interval] for categorical variables.

224

225

226

227 Table 2. Biomarker levels in maternal blood

		ACAP2	LOC101927441	ZNF324	SH3PXD2B	TBX21
TERM	T1 (n=40)	11649[10656-12641]	546[479-613]	572[513-631]	27[18-36]	1128[1003
	T2 (n=43)	10711[9727-11695]	465[397-533]	484[432-536]	24[17-31]	989[852-1
SPTL	T1 (n=44)	9868[8744-10629]	422[364-480]	444[394-494]	21[17-25]	895[757-1
	T2 (n=42)	11827[10049-13605]	471[388-554]	515[443-587]	39[26-52]	1042[864-

228 Values are represented as mean [95% confidence interval] of mean fluorescence index MFI.

229

230

231 Four of the five measured biomarkers, ACAP2 (p=0.0068), LOC101927441 (p=0.0082),

232 ZNF324 (p=0.0019), and TBX21 (p=0.0182) exhibited significantly lower levels in the sPTL

233 group compared to the term group at T1, and not at T2. When assessing biomarkers as a

234 measurement of T2/T1 ratios, ACAP2 (p=0.0074), LOC101927441 (p=0.0273), ZNF324

(p=0.0170), TBX21 (p=0.0119) ratios were significantly higher in the sPTL group than the term 235

236 group, suggesting a greater trajectory of increased expression through gestation in those with

237 sPTL (Fig 1). Though we do observe some differences in biomarker levels between sPTL and

It is made available under a CC-BY 4.0 International license .

term samples, only five of the eight originally identified biomarkers [22] could be measured

using the same population and methodology, and only four exhibited significant differences

between term and preterm groups.

241

242

Figure 1. Biomarkers of preterm birth. Values are reported as mean fluorescence index (MFI)
at either timepoint or a ratio of MFI values at T2 over T1. Analysed by one-way ANOVA
followed by Dunnett correction for multiple comparisons. *p-value<0.05, **p-value<0.01. *ACAP2*: ArfGAP with coiled-coil, ankyrin repeat and PH domains 2, *ZNF324*: zinc finger
protein 324. *SH3PCD2B*: SH3 and PX domains 2B, *TBX21*: T-box transcription factor 21.

248

249 Novel prediction model: Feature selection

250 In the interest of identifying other potential biomarkers that can robustly predict sPTB, 251 we conducted feature selection analysis on the publicly available AOF microarray dataset 252 (GSE59491) [22]. The top gene features selected from the complete microarray dataset, along 253 with their assigned gene scores for each iteration of cross validation (two times five-fold cross 254 validation for a total of ten iterations), are represented in Table 3. Notably, the top predictive 255 genes did not show consistency in assigned gene scores across iterations. The topmost 256 explanatory feature as selected by the feature selection algorithm, FPR3 dT, was assigned a score 257 of 1 (#1 most predictive) and 2 (#2 most predictive) but was assigned a score of zero 258 (uninformative) the remaining eight iterations, indicating that top features are not robust to noise 259 within the dataset.



It is made available under a CC-BY 4.0 International license .

Feature	Iteration:	1	2	3	4	5	6	7	8	9	10
FPR3 dT		0	0	0	0	0	1	0	2	0	0
Formyl peptide receptor	3										
<i>TRBJ2-6</i> T1		0	0	0	1	0	0	0	0	0	2
T cell receptor beta joini	ng 2-6										
<i>PLD4</i> T2		0	0	0	12	0	0	4	0	0	0
phospholipase D family	member 4										
<i>ZFP14</i> T2		0	0	0	0	1	0	0	0	0	0

zinc finger protein

Rows represent top four overall explanatory genetic features selected. Columns represent
individual analysis (2 times 5-times cross validation for a total of 10 iterations). Values represent
predictive score assigned by the feature selection algorithm where 1 is the highest possible value,
indicating the most predictive genetic feature and a score of 0 indicates that the feature was not
considered predictive for that given iteration.

266

267 Model performance for prediction of sPTB

The MLP model showed promising performance in the training set (area under the receiver operating curve, AUC 0.9), and an improvement over traditional LR (AUC 0.85), though performance was notably degraded when applied to the internal test set (AUC 0.54), and further degraded when validated externally (AUC 0.51 MLP, AUC 0.53 LR), which indicates a high degree of overfitting (Table 4).

273 Table 4. Model Performance

Model	Training Set	Test Set	Training AUC	Test AUC
MLP	Calgary	Calgary	0.90	0.54
LR	Calgary	Calgary	0.85	0.54

It is made available under a CC-BY 4.0 International license .

MLP	Calgary	Detroit	0.74	0.51
LR	Calgary	Detroit	0.77	0.53

Model performance as reported by area under the receiver operating curve (AUC) for two
 prediction algorithms, multilayer perceptron (MLP) and logistic regression (LR) validated
 internally and externally.

277

278

279 Assessing overfitting

280 Both LR and MLP models showed significant degradation of performance in both internal and external test sets as compared to training performance, indicating a high degree of 281 282 overfitting during training, particularly in the MLP model. To test the degree of overfitting, 283 models were retrained using permuted data. In brief, target labels (sPTL or term) were scrambled 284 to remove any potential true pattern within the data before proceeding with model training as 285 before. Using scrambled data, high performance was still observed in the training set, with the 286 highest performance by the MLP algorithm (AUC 0.80). Model performance was degraded when 287 applied to either the internal or external test sets (Table 5).

288 Table 5. Model performance using permuted data

Model	Training Set	Test Set	Training AUC	Test AUC
MLP	Calgary	Calgary	0.80	0.49
LR	Calgary	Calgary	0.75	0.50
MLP	Calgary	Detroit	0.72	0.52
LR	Calgary	Detroit	0.63	0.52

It is made available under a CC-BY 4.0 International license .

Model performance as reported by area under the receiver operating curve (AUC) for two
prediction algorithms, multilayer perceptron (MLP) and logistic regression (LR) tested internally
and validated externally.

292

293

294 **Discussion**

295 We were unable to repeat the findings of Heng et al., [22] to predict spontaneous preterm 296 birth using maternal blood gene expression. Most alarmingly, two of the eight topmost predictive 297 genes were not detectable in blood samples from the same patients, suggesting issues with 298 repeatability in probe-based RNA array methods, despite validation of RNA integrity over long-299 term storage [23]. Indeed, array reliability may be particularly problematic in lowly expressed 300 genes and certain genes may be more subject to poor probe specificity [33, 34], and we were 301 unable to conduct assessment of gene-specific expression levels over long-term storage. 302 Additionally, we were unable to produce a more generalizable model through secondary analysis 303 of the microarray data using machine learning, and our results suggest a high degree of 304 overfitting following external validation. This highlights the importance of repeat and validation 305 studies in order to meaningfully progress the field of preterm birth prediction.

306 One of the primary limitations to prediction using maternal blood gene expression 307 encountered was overfitting and noise within the dataset, which significantly skewed 308 performance estimates. A noisy dataset likely also contributed to the inability to repeat and/or 309 validate previous findings. Possible consequences of data noise are further exacerbated when 310 using advanced methods such as machine learning, and, as evidenced in the study herein, high 311 complexity/machine learning approaches often do not demonstrate improved predictive

312 performance over traditional statistical methods [35]. Feature selection approaches were unable 313 to effectively reduce the noise within this dataset to obtain clinically useful patterns as markers 314 for spontaneous preterm birth. Many prediction studies, at least in the field of reproduction, are 315 preceded by observational experiments to explore biomarker patterns as possible predictors, such 316 as differential gene expression analysis to identify genes associated with an outcome. Often, 317 these observational experiments are conducted on the whole dataset, not the training set, and as 318 such, prediction models trained on this data are biased by patterns that exist in the test set. This 319 phenomenon, in which information from outside the training dataset is used to create the 320 prediction model, is known as data leakage. Consequently, the training dataset contains 321 information about the outcome that would not be otherwise available when using the model for 322 prediction, artificially overinflating the predictive performance when the model is applied to the 323 test set. Unintentional data leakage likely contributes to the lack of reproducibility in such 324 prediction studies. High levels of noise inherent in gene expression data exacerbated the 325 consequences of data leakage during differential expression analysis and feature selection, 326 highlighting the importance of cautious interpretation and robust methodological safeguards. 327 To illustrate the extent to which data leakage may impact performance results, we also performed model training in the training set in which differential expression analysis was 328 329 conducted *before* the splitting the training and test sets (S1 Table). While we observe high 330 predictive performance in the training set (AUC 0.72 with LR, 0.79 with MLP), performance 331 was not significantly degraded in the test set (AUC 0.65 with LR, 0.85 with MLP). Note that

332 with the presence of data leakage, the machine learning MLP model had substantially higher

performance (AUC 0.85) as compared to analysis without data leakage (AUC 0.54 for

334 comparable dataset). This stresses the importance of methodological safeguarding and careful

It is made available under a CC-BY 4.0 International license .

335 study design, to avoid possible sources of bias and data leakage, particularly in omics or similar 336 datasets that are prone to a high degree of noise. External validation is also a highly powerful 337 tool for testing the generalizability of models that may have been subject to data leakage. 338 Our findings also underscore the broader implications for omics studies for discovery 339 analysis, where high feature-to-observation ratios are common, which exacerbates the challenge 340 for mitigating bias and ensuring the reliability of predictive models. For example, differential 341 expression analysis without appropriate training and testing sets for validation introduces 342 inherent bias and limits the generalizability of patterns identified. Testing on internal test sets 343 alone is insufficient for measuring generalizability, especially in the instance of data leakage. 344 Yet, assessments of overfitting and external validation are not standard practice in preterm birth 345 prediction, and the authors stress their importance for meaningful future work in this field. As 346 such, our study serves as a cautionary tale for researchers, emphasizing the need for 347 transparency, rigorous methodological standards, as well as not only repeating results but 348 validation in external cohorts in order to advance the field of spontaneous preterm birth 349 prediction responsibly.

350 While maternal blood presents an enticing opportunity for minimally invasive prediction, 351 peripheral blood is subject to a high noise signal from various physiological processes occurring 352 within the body possibly unrelated to uterine function during pregnancy. This stresses the need 353 for improved feature identification. Biological compartments including cervicovaginal fluid, 354 amniotic fluid, and the vaginal microbiome may better reflect the physiology of pregnancy [36, 355 37] though sample availability of reproductive and gestational tissues for research purposes are limited. An emerging strategy involves the use of cell-free nucleic acid biomarkers, which can be 356 357 utilized to identify biomarkers with uterine origin in maternal blood for improved prediction of

It is made available under a CC-BY 4.0 International license .

358 adverse pregnancy outcomes [38, 39]. Considerable research has been conducted to review the 359 most robust predictors for sPTB, including but not limited to inflammatory biomarkers, maternal 360 characteristics and genetic contributions [40-42], yet the most frequently used risk factors in 361 current literature show variable predictive performance and poor robustness [43]. A recent meta-362 analysis identified the most robust predictors of PTB, including low gestational weight gain, 363 interpregnancy interval following miscarriage <6months, and sleep-disordered breathing [42], 364 and it is likely that combined biomarker approaches are necessary for prediction [44, 45]. 365 Additionally, current literature often does not distinguish those predictors for general PTB from 366 those for sPTB, despite likely distinct aetiologies. It is also worth noting that the pervasive use of 367 convenience sampling in reproductive studies (e.g. secondary analysis of biosamples used for 368 routine antenatal screening) are not necessarily performed proximal to the outcome of interest 369 (PTB). For many subjects, the delay from testing to outcome may make identifying true 370 associations difficult.

371 Looking ahead, our recommendations for future research include safeguarding against 372 sources of data leakage, implementing cross-validation techniques as a measure of robustness, 373 and prioritizing repeatability and reproducibility of findings. This likely includes incentivizing 374 repeated studies in published literature and improving data management, storage, and sharing 375 infrastructure [10, 11]. Additionally, as unsupervised feature selection techniques were not 376 shown to be beneficial in improving prediction of spontaneous preterm birth, future research in 377 identifying biomarkers for the mechanism preterm labour are important. The best models 378 combine an understanding of the features (such as genes, proteins, or patient characteristics) that 379 are most important for determining the outcome and robust methodologies. In the case of 380 spontaneous preterm birth, this should involve a return to the bench to better elucidate those

381	pathways and biomarkers and their possible contribution to preterm birth outcomes. In better							
382	understanding the mechanisms of labour and preterm birth, we stand to better approach its							
383	predict	prediction, and consequently, improving maternal and neonatal health outcomes for those						
384	impact	ed by preterm birth.						
385								
386								
387	Refe	erences						
388	1.	Ohuma EO, Moller AB, Bradley E, Chakwera S, Hussain-Alkhateeb L, Lewin A, et al. National,						
389	regiona	l, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis.						
390	Lancet.	2023;402(10409):1261-71.						
391	2.	Purisch SE, Gyamfi-Bannerman C. Epidemiology of preterm birth. Seminars in Perinatology.						
392	2017;4	1(7):387-91.						
393	3.	Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al. Global, regional, and						
394	nationa	l causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the						
395	Sustain	able Development Goals. Lancet Child Adolesc Health. 2022;6(2):106-15.						
396	4.	Hornaday KK, Wood EM, Slater DM. Is there a maternal blood biomarker that can predict						
397	spontan	neous preterm birth prior to labour onset? A systematic review. PLOS ONE. 2022;17(4):e0265853.						
398	5.	Marić I, Stevenson DK, Aghaeepour N, Gaudillière B, Wong RJ, Angst MS. Predicting Preterm						
399	Birth U	sing Proteomics. Clin Perinatol. 2024;51(2):391-409.						
400	6.	Ramachandran A, Clottey KD, Gordon A, Hyett JA. Prediction and prevention of preterm birth:						
401	Quality	assessment and systematic review of clinical practice guidelines using the AGREE II framework.						
402	Int J Gy	vnaecol Obstet. 2024.						

It is made available under a CC-BY 4.0 International license .

- 403 7. Yang Q, Fan X, Cao X, Hao W, Lu J, Wei J, et al. Reporting and risk of bias of prediction models
- 404 based on machine learning methods in preterm birth: A systematic review. Acta Obstet Gynecol Scand.

405 2023;102(1):7-14.

- 406 8. Staffa SJ, Zurakowski D. Statistical Development and Validation of Clinical Prediction Models.
- 407 Anesthesiology. 2021;135(3):396-405.
- 408 9. Steyerberg EW, Harrell FE, Jr. Prediction models need appropriate internal, internal-external, and
 409 external validation. J Clin Epidemiol. 2016;69:245-7.
- 410 10. Sharifi-Heris Z, Laitala J, Airola A, Rahmani AM, Bender M. Machine Learning Approach for
- 411 Preterm Birth Prediction Using Health Records: Systematic Review. JMIR Med Inform.
- **412** 2022;10(4):e33875.
- 413 11. Mennickent D, Rodríguez A, Opazo MC, Riedel CA, Castro E, Eriz-Salinas A, et al. Machine
- 414 learning applied in maternal and fetal health: a narrative review focused on pregnancy diseases and
- 415 complications. Front Endocrinol (Lausanne). 2023;14:1130139.
- 416 12. Leisman DE, Harhay MO, Lederer DJ, Abramson M, Adjei AA, Bakker J, et al. Development
- 417 and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and
- 418 Critical Care Journals. Crit Care Med. 2020;48(5):623-33.
- 419 13. Collins GS, Dhiman P, Ma J, Schlussel MM, Archer L, Van Calster B, et al. Evaluation of
- 420 clinical prediction models (part 1): from development to external validation. Bmj. 2024;384:e074819.
- 421 14. Lenain R, Dantan E, Giral M, Foucher Y, Asar Ö, Naesens M, et al. External Validation of the
- 422 DynPG for Kidney Transplant Recipients. Transplantation. 2021;105(2):396-403.
- 423 15. Russell FM, Herbert A, Kennedy S, Nti B, Powell M, Davis J, et al. External validation of the
- 424 ultrasound competency assessment tool. AEM Educ Train. 2023;7(3):e10887.
- 425 16. Yun JS, Han K, Choi SY, Cha SA, Ahn YB, Ko SH. External validation and clinical application
- 426 of the predictive model for severe hypoglycemia. Front Endocrinol (Lausanne). 2022;13:1006470.

- 427 17. Slieker RC, van der Heijden A, Siddiqui MK, Langendoen-Gort M, Nijpels G, Herings R, et al.
- 428 Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and
- 429 external validation study. Bmj. 2021;374:n2134.
- 430 18. Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction.
- 431 Am J Obstet Gynecol. 2022;226(2s):S1071-S97.e2.
- 432 19. Neary C, Naheed S, McLernon DJ, Black M. Predicting risk of postpartum haemorrhage: a
- 433 systematic review. Bjog. 2021;128(1):46-53.
- 434 20. Van Calster B, Steyerberg EW, Wynants L, van Smeden M. There is no such thing as a validated
- 435 prediction model. BMC Medicine. 2023;21(1):70.
- 436 21. Feyaerts D, Marić I, Arck PC, Prins JR, Gomez-Lopez N, Gaudillière B, et al. Predicting
- 437 Spontaneous Preterm Birth Using the Immunome. Clin Perinatol. 2024;51(2):441-59.
- 438 22. Heng YJ, Pennell CE, McDonald SW, Vinturache AE, Xu J, Lee MWF, et al. Maternal whole
- 439 blood gene expression at 18 and 28 weeks of gestation associated with spontaneous preterm birth in
- 440 asymptomatic women. PLoS ONE. 2016;11(6).
- 441 23. Stephenson NL, Hornaday KK, Doktorchik CTA, Lyon AW, Tough SC, Slater DM. Quality
- 442 assessment of RNA in long-term storage: The All Our Families biorepository. PLoS One.
- **443** 2020;15(12):e0242404.
- 444 24. Alpaydin E. Introduction to machine learning. Ieee Xplore d, Mit Press p, ebrary I, editors:
- 445 Cambridge, Massachusetts : MIT Press; Third edition.; 2014.
- 446 25. Theodoridis S. Machine learning : a Bayesian and optimization perspective: Amsterdam,
- 447 Netherlands : Academic Press; First edition.; 2015.
- 448 26. Dhar V. Data science and prediction. Commun ACM. 2013;56(12):64–73.
- 449 27. Arain Z, Iliodromiti S, Slabaugh G, David AL, Chowdhury TT. Machine learning and disease
- 450 prediction in obstetrics. Curr Res Physiol. 2023;6:100099.

- 451 28. McDonald CR, Darling AM, Conroy AL, Tran V, Cabrera A, Liles WC, et al. Inflammatory and
- 452 angiogenic factors at mid-pregnancy are associated with spontaneous preterm birth in a cohort of
- 453 Tanzanian women. PLoS ONE. 2015;10(8).
- 454 29. Gracie SK, Lyon AW, Kehler HL, Pennell CE, Dolan SM, McNeil DA, et al. All Our Babies
- 455 Cohort Study: recruitment of a cohort to predict women at risk of preterm birth through the examination
- 456 of gene expression profiles and the environment. BioMed Central; http://www.biomedcentral.com/1471-
- 457 <u>2393/10/87;University</u> of Calgary;Medicine; 2011.
- 458 30. Tough SC, McDonald SW, Collisson BA, Graham SA, Kehler H, Kingston D, et al. Cohort
- 459 Profile: The All Our Babies pregnancy cohort (AOB). International Journal of Epidemiology.
- **460** 2017;46(5):1389-90k.
- 461 31. Tarca AL, Pataki BÁ, Romero R, Sirota M, Guan Y, Kutum R, et al. Crowdsourcing assessment
- 462 of maternal blood multi-omics for predicting gestational age and preterm birth. Cell Reports Medicine.
- 463 2021;2(6):100323-.
- 464 32. Werbicki T. Slater-Lab-SPTB2022. Available from: <u>https://github.com/tywerbicki/Slater-Lab-</u>
 465 <u>SPTB</u>.
- 466 33. Draghici S, Khatri P, Eklund AC, Szallasi Z. Reliability and reproducibility issues in DNA
 467 microarray measurements. Trends Genet. 2006;22(2):101-9.
- 468 34. Kothapalli R, Yoder SJ, Mane S, Loughran TP, Jr. Microarray results: how accurate are they?
 469 BMC Bioinformatics. 2002;3:22.
- 470 35. Christodoulou E, Ma J, Collins GS, Steyerberg EW, Verbakel JY, Van Calster B. A systematic
- 471 review shows no performance benefit of machine learning over logistic regression for clinical prediction
- 472 models. J Clin Epidemiol. 2019;110:12-22.
- 473 36. Chakoory O, Barra V, Rochette E, Blanchon L, Sapin V, Merlin E, et al. DeepMPTB: a vaginal
- 474 microbiome-based deep neural network as artificial intelligence strategy for efficient preterm birth
- 475 prediction. Biomarker Research. 2024;12.

It is made available under a CC-BY 4.0 International license .

- 476 37. Chang Y, Li W, Shen Y, Li S, Chen X. Association between interleukin-6 and preterm birth: a
- 477 meta-analysis. Ann Med. 2023;55(2):2284384.
- 478 38. Cowan AD, Rasmussen M, Jain M, Tribe RM. Predicting Preterm Birth Using Cell-Free
- 479 Ribonucleic Acid. Clin Perinatol. 2024;51(2):379-89.
- 480 39. Moufarrej MN, Vorperian SK, Wong RJ, Campos AA, Quaintance CC, Sit RV, et al. Early
- 481 prediction of preeclampsia in pregnancy with cell-free RNA. Nature. 2022;602(7898):689-94.
- 482 40. Tang ID, Mallia D, Yan Q, Pe'er I, Raja A, Salleb-Aouissi A, et al. A Scoping Review of Preterm
- 483 Birth Risk Factors. Am J Perinatol. 2024;41(S 01):e2804-e17.
- 484 41. Li J, Ge J, Ran N, Zheng C, Fang Y, Fang D, et al. Finding the priority and cluster of
- 485 inflammatory biomarkers for infectious preterm birth: a systematic review. J Inflamm (Lond).
- **486** 2023;20(1):25.
- 487 42. Mitrogiannis I, Evangelou E, Efthymiou A, Kanavos T, Birbas E, Makrydimas G, et al. Risk
- 488 factors for preterm birth: an umbrella review of meta-analyses of observational studies. BMC Med.
- **489** 2023;21(1):494.
- 490 43. Ferreira A, Bernardes J, Gonçalves H. Risk Scoring Systems for Preterm Birth and Their
- 491 Performance: A Systematic Review. J Clin Med. 2023;12(13).
- 492 44. Mirzaei A, Hiller BC, Stelzer IA, Thiele K, Tan Y, Becker M. Computational Approaches for
- 493 Connecting Maternal Stress to Preterm Birth. Clin Perinatol. 2024;51(2):345-60.
- 494 45. Creswell L, Rolnik DL, Lindow SW, O'Gorman N. Preterm Birth: Screening and Prediction. Int J
- 495 Womens Health. 2023;15:1981-97.
- 496
- 497

498 Supporting Information

- 499 S1 Table. Model performance with data leakage. LR: logistic regression, MLP: multilayer
- 500 perceptron, AUC: area under the receiver operating curve. Trained on the Calgary dataset and
- 501 tested on the Calgary test set.
- 502 S2 Table. Raw fluorescence index for predictive genes tested in maternal blood. Isolated
- 503 RNA from whole maternal blood was analyzed for gene expression using a QuantiGene Plex
- 504 custom assay (Qiagen).

ACAP2 at T1 LOC101927441 at T1

ZNF324 at T1



ACAP2

LOC101927441

ZNF324

SH3PXD2B

TBX21











Figure